Serimmune
US-based Serimmune Inc., founded in 2014, specializes in commercial physical and biological R&D.
Founded
2014US-based Serimmune Inc., founded in 2014, specializes in commercial physical and biological R&D.
Serimmune Inc., founded in 2014 and based in Goleta, United States, is an immune intelligence company specializing in commercial physical and biological research and development. The company's core mission is to decode the breadth and complexity of human antibody responses. Serimmune offers a universal serology assay that identifies disease-specific epitopes across proteins and entire proteomes, empowering discovery projects and advancing precision medicine. Their market focus includes healthcare providers, researchers, and pharmaceutical companies aiming to understand immune responses for better diagnostics and treatments.
Notable affiliated people include experienced scientists and industry leaders in immunology and biotechnology. Serimmune has garnered attention for its innovative SERA platform, which has been used to identify features of Long COVID, showcasing its potential in addressing contemporary health challenges. The company's key achievements include advancing immune profiling services that contribute significantly to precision medicine. Overall, Serimmune's impact lies in its ability to provide deeper insights into immune responses, aiding in the development of targeted therapies and improving patient outcomes.
Companies similar to Serimmune include ImmuneID, ImmuneTarget, Immunai and SeromYx Systems.
Serimmune was founded in 2014.
Serimmune's headquarters is located in Goleta, CA, US.
Serimmune's most recent funding round was for $12M (USD) in September 2020.
As of Sep 11, 2020, Serimmune has raised a total of $21.4M (USD).
Serimmune has 24 employees as of Feb 5, 2024.
